Aro Biotherapeutics, a Philadelphia, PA-based clinical stage biotechnology company, raised $41.5M in Series B funding.
The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners, L.P. In conjunction with the financing, Christopher Picariello, President, JJDC, has joined Aro’s Board of Directors.
The company intends to use the funds to support progression of its pipeline of Centyrin-siRNA programs, including ABX1100, a novel potential treatment for Pompe Disease. In addition, the Series B funding will support new Centyrin-siRNA conjugate programs focused on the discovery of new therapies for autoimmune disorders.
Led by Susan Dillon, Ph.D., CEO, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a pipeline of Centyrin-based therapeutic candidates for tissue-specific targeting of therapeutics for a diverse set of diseases.
Aro recently announced the start of a first-in-human with ABX1100, and the Company anticipates that initial data from this study will be presented in 2024.
FinSMEs
28/11/2023